Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of SHR1459 combined with YY-20394 in relapsed or refractory B-cell non-Hodgkin lymphoma
CTR20211639Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of edralbrutinib, linperlisib in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), sponsored by Hengrui Therapeutics. Started Jul 2021; status: active.
02
Drugs
edralbrutiniblinperlisib
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20211639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211639.